Why Compare Wegovy vs Mounjaro Instead of Ozempic?
Wegovy vs Ozempic vs Mounjaro: Understanding the Key Differences
When searching for "wegovy vs ozempic," it's crucial to understand that Ozempic and Wegovy contain the same active ingredient (semaglutide) but serve different licensed purposes. Ozempic is licensed exclusively for type 2 diabetes management, whilst Wegovy is specifically licensed by the MHRA for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Promoting Wegovy for weight management would constitute off-label use outside its licensed indication. The meaningful comparison for weight management is actually between Wegovy (semaglutide) and Mounjaro (tirzepatide), both of which are licensed for weight management and available through EverydayMeds.
Mounjaro represents a different therapeutic approach entirely, utilising tirzepatide as a dual GIP and GLP-1 receptor agonist. This dual mechanism targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, whereas Wegovy focuses solely on GLP-1 receptor activation. Both prescription-only medicines require clinical assessment and ongoing prescriber oversight, but their different mechanisms may suit different patient profiles and treatment goals.
Wegovy vs Mounjaro Pricing and Value Comparison
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro, allowing you to compare costs across different dose escalation phases. Wegovy follows a five-dose escalation from 0.25mg (£79.99) through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg (£209.99). New customers apply code FIRST40 at checkout, whilst returning customers use code DOSE25. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) provide two months' initial supply for £169.99, streamlining your early treatment phase.
Mounjaro pricing follows its own six-dose escalation pathway, with different cost considerations reflecting its dual-agonist formulation and manufacturing complexity. Both medications require the same clinical assessment process and next-day cold-chain delivery from our GPhC-registered pharmacy. The total treatment cost will depend on your individual dose requirements, tolerance, and treatment duration, factors which your prescriber will discuss during clinical review.
Clinical Evidence: STEP Trials vs SURMOUNT Data
Wegovy's clinical evidence comes primarily from the STEP trial programme, where patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro's evidence base stems from the SURMOUNT trials, though direct head-to-head comparisons between Wegovy and Mounjaro aren't possible due to different trial designs, populations, and endpoints. Both medications showed substantial weight management effects in their respective clinical programmes, but individual responses may vary considerably based on patient characteristics, adherence, and lifestyle factors.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of naturally occurring glucagon-like peptide-1 hormone. This hormone is normally released from intestinal cells in response to food intake and helps regulate appetite and satiety signals in the brain. By activating GLP-1 receptors, Wegovy may help reduce appetite, promote feelings of fullness after smaller meals, and potentially reduce food cravings by working on hypothalamic appetite centres. The medication slows gastric emptying, which contributes to prolonged satiety and reduced caloric intake when used alongside a reduced-calorie diet and increased physical activity.
EverydayMeds Ordering Process for Both Medications
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any contraindications. Following submission, our qualified prescribers conduct thorough clinical review within 3 working days (or 24 hours with express service) to determine suitability for either Wegovy or Mounjaro. Once approved, your prescription-only medicine ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and pharmaceutical quality standards throughout the supply chain.
Storage and Practical Considerations
Wegovy offers a practical advantage in storage flexibility, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use and come in pre-filled FlexTouch injection pens for convenient once-weekly administration. Wegovy follows a mandatory dose escalation schedule over 16 weeks to reach the 2.4mg maintenance dose, whilst Mounjaro has its own escalation pathway to optimise tolerability. Neither medication should be frozen, and proper disposal of used pens follows standard sharps disposal protocols.
Wegovy vs Mounjaro: Mechanism and Tolerability Profiles
The fundamental difference between these medications lies in their receptor targeting: Wegovy's semaglutide activates GLP-1 receptors exclusively, whilst Mounjaro's tirzepatide provides dual GIP and GLP-1 receptor activation. This dual mechanism may offer different tolerability profiles and efficacy patterns, though individual responses vary significantly. Some patients may find one medication more suitable based on their specific side effect tolerance, injection preferences, or metabolic profile.
Both medications carry similar contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Your prescriber will evaluate your medical history, current medications, and individual risk factors to determine which option aligns best with your clinical profile and treatment objectives.
Start Your Weight Management Journey Today
Both Wegovy and Mounjaro are available through EverydayMeds with the same rigorous clinical standards and pharmaceutical quality assurance. New customers can begin their clinical assessment today using code FIRST40, whilst returning customers benefit from code DOSE25 at checkout. Our clinical team provides ongoing support throughout your treatment journey, with prescriber consultations available to optimise dosing and address any concerns. Visit https://everydaymeds.co.uk/collections/weight-loss to compare both options and begin your personalised clinical assessment. Your prescriber can help determine which medication best suits your individual circumstances and weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
